The European Medicines Agency recommends authorizing Novavax’ Nuvaxovid vaccine targeting Covid-19’s JN.1 variant, according to a post by the regulator on X.
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2025 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.